Comparison 73. DaxibotulinumtoxinA 60 units versus placebo one cycle of treatment in glabellar lines.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
73.1 Participants assessment of success by analysing scores and scales	1		Risk Ratio (IV, Random, 95% CI)	Totals not selected
73.1.1 4 weeks	1		Risk Ratio (IV, Random, 95% CI)	Totals not selected
73.1.2 16 weeks	1		Risk Ratio (IV, Random, 95% CI)	Totals not selected
73.1.3 24 weeks	1		Risk Ratio (IV, Random, 95% CI)	Totals not selected
73.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
73.3 Physician assessment of success by analysing scores and scales	1		Risk Ratio (IV, Random, 95% CI)	Totals not selected
73.3.1 4 weeks	1		Risk Ratio (IV, Random, 95% CI)	Totals not selected
73.3.2 8 weeks	1		Risk Ratio (IV, Random, 95% CI)	Totals not selected
73.3.3 12 weeks	1		Risk Ratio (IV, Random, 95% CI)	Totals not selected
73.3.4 16 weeks	1		Risk Ratio (IV, Random, 95% CI)	Totals not selected
73.3.5 20 weeks	1		Risk Ratio (IV, Random, 95% CI)	Totals not selected
73.3.6 24 weeks	1		Risk Ratio (IV, Random, 95% CI)	Totals not selected
73.4 Total adverse events	1		Risk Ratio (IV, Random, 95% CI)	Totals not selected
73.5 Duration of treatment	1		Mean Difference (IV, Random, 95% CI)	Totals not selected